黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券换股价格调整的提示性公告

Group 1 - The core point of the announcement is that Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has received a notification from its controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., regarding the adjustment of the conversion price for the first phase of the non-public issuance of exchangeable bonds [1][2] - The first phase of the exchangeable bonds, referred to as "23 Chuang01EB," was issued on April 11, 2023, with a total scale of 910 million yuan and a term of three years [1] - The conversion price for the exchangeable bonds will be automatically adjusted from 7.75 yuan per share to 7.30 yuan per share due to the stock price falling below 10 yuan per share for at least 10 trading days within a 30-day period [2] Group 2 - The adjusted conversion price will take effect on March 2, 2026, and the number of shares prepared for exchange in the pledge account of the exchangeable bonds will still meet the requirements for full conversion [2] - The company will closely monitor the progress of the exchangeable bonds and fulfill its continuous information disclosure obligations as required [2]